Results 111 to 120 of about 8,508 (214)
Drug Design, Development and Therapy, 2016 Liu QY, He MM, Shi H, et al. Drug Des Devel Ther. 2015;9: 2527–2535. In “Efficacy and safety of different doses of a slow release corticosteroid implant for macular edema: meta-analysis of randomized controlled trials” published ...
Liu QY +8 more
doaj
Subconjunctival dexamethasone implant for non-necrotizing scleritis [PDF]
, 2013 BACKGROUND: The purpose of this study is to report the management of non-necrotizing anterior scleritis with a single-dose subconjunctival 0.7 mg dexamethasone implant (Ozurdex®, Allergan, Inc., CA, USA).
Cristina Muccioli +4 more
core +1 more source
Efficacy and safety of different doses of a slow release corticosteroid implant for macular edema
Drug Design, Development and Therapy, 2016 John Hall Medical Affairs, Alimera Sciences Ltd., Aldershot, Hampshire, UKI read “Efficacy and safety of different doses of a slow release corticosteroid implant for macular edema: meta-analysis of randomized controlled trials” published in ...
Hall J
doaj
BMC Ophthalmology, 2017 Background AZOOR was first described by Gass in 1993 as a syndrome with rapid loss of one or more extensive zones of the outer retinal segments. It is characterized by photopsia, minimal funduscopic changes, and electroretinographic abnormalities.
Yi Chun Kuo, Nancy Chen, Rong Kung Tsai
doaj +1 more source
Intravitreal bevacizumab associated with grid laser photocoagulation in macular edema secondary to branch retinal vein occlusion [PDF]
, 2011 To evaluate intravitreal bevacizumab (IVB) combined with grid laser photocoagulation in macular edema (ME) secondary to branch retinal vein occlusion (BRVO). METHODS: Eight eyes (8 patients) with ME associated with BRVO with at least
Barrio-Barrio, J. (Jesús) +5 more
core
Sustained-release steroids for the treatment of diabetic macular edema. [PDF]
, 2015 Glucocorticoids have been used for decades in the treatment of ocular disorders via topical, periocular, and more recently intravitreal routes. However, their exact mechanisms of action on ocular tissues remain imperfectly understood.
Behar-Cohen, F., Daruich, A., Matet, A.
core +1 more source
Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial [PDF]
, 2015 Purpose: To evaluate the efficacy and safety of dexamethasone intravitreal implant 0.7 mg (DEX) as adjunctive therapy to ranibizumab in neovascular age-related macular degeneration (nvAMD). Procedures: This was a 6-month, single-masked, multicenter study.
Adnan Tufail +11 more
core +1 more source
, 2020 Although fluoride (F) is a fundamental anion for keeping human body strong, a high consumption could lead to real medical health hazard issues. The observation of fine drinking water as key consumption route is the important aspect in preventing its negative results on well-being.
openaire +2 more sources
Intravitreal triamcinolone acetonide injection in the treatment of Vogt-Koyanagi-Harada syndrome [PDF]
, 2004 PURPOSE: To report the use of intravitreal injection of triamcinolone acetonide in the acute phase of Vogt-Koyanagi-Harada's disease. METHODS: Nine eyes from five patients in the acute phase of Vogt-Koyanagi-Harada's disease with serous retinal ...
Andrade, Rafael Ernane Almeida +2 more
core +3 more sources
Scientific ReportsIn cases of an unstable iris-lens diaphragm, intravitreal corticosteroid slow-release implants (CSRI) may accidentally migrate into the anterior chamber, leading to damage to the corneal endothelium. The purpose of this study was to evaluate the efficacy
Ben Asani +7 more
doaj +1 more source